|
|
||||||||||||||
|
|
|||||||||||||||
EDITORIALS |
1 Department of Histopathology, Faculty of Medicine, St Marys Campus, Imperial College, London, UK
2 Department of Microbiology, Mid Essex Hospital NHS Trust, Broomfield Hospital, Chelmsford, Essex, UK
3 HPA Primary Care Unit, Microbiology Department, Gloucestershire Royal Hospital, Gloucester, UK
Correspondence to:
Dr M M Walker, Department of Histopathology, Faculty of Medicine, St Marys Campus, Imperial College, London W2 1PG, UK; mm.walker@imperial.ac.uk
Keywords: gastric cancer; Helicobacter pylori
| The first 150 words of the full text of this article appear below. |
Worldwide, gastric cancer is still a leading cause of cancer deaths. The association of Helicobacter pylori and gastric cancer is well established, and the bacterium was declared a class one carcinogen by the International Agency for Research on Cancer and the World Health Organisation in 1994. H pylori infection is responsible for 5.5% of all global cancers, 75% of non-cardia gastric cancer and lymphoma, and 65% of gastric cancers worldwide.1
In 2005, Marshall and Warren were awarded the Nobel Prize for Medicine for their pioneering work on H pylori (in 1984) showing the association between this bacterium and gastritis and that antibiotics could cure peptic ulcers.2 Parsonnet et al3 formally demonstrated the link to gastric cancer in 1991. However, although more than 50% of people worldwide are infected with H pylori, only a small percentage of those infected will have clinical complications, which include gastric and duodenal ulcers, precancerous
Relevant Article
Postgrad. Med. J. 2008 84: 193-197.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |